We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2007 by Korea Otsuka Pharmaceutical Co., Ltd..
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00549952
First Posted: October 26, 2007
Last Update Posted: October 26, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Information provided by:
Korea Otsuka Pharmaceutical Co., Ltd.
  Purpose
to survey oral mucositis after chemotherapy and Concurrent chemoradiotherapy in Korean cancer patients

Condition Intervention
Oral Mucositis Other: no intervention study

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients

Further study details as provided by Korea Otsuka Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • incidence and severity of oral mucositis

Study Start Date: October 2007
Estimated Study Completion Date: March 2008
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients diagnosed with one cancer among head and neck cancer, esophageal cancer, breast cancer, colorectal cancer, gastric cancer, and non-small cell lung cancer, who are being treated or going to be treated as one between A and B A. Chemotherapy only B. Concurrent chemoradiotherapy

Exclusion Criteria:

  • Patients who are pregnant or breast feeding, absent from effective(medically proven) contraceptive method for females of childbearing potential
  • Patients with performance status of ECOG score is more than 3
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00549952


Contacts
Contact: Yonghui Jeong 82-2-3465-3956 jeongyh@otsuka.co.kr
Contact: Boyoun Seo 82-2-3465-5485 byseo@otsuka.cokr

Locations
Korea, Republic of
Seoul National University hospital Recruiting
Seoul, Korea, Republic of, 110-744
Principal Investigator: Do-Youn Oh         
Sponsors and Collaborators
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Investigators
Principal Investigator: Do-Youn Oh, PhD Seoul National University Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00549952     History of Changes
Other Study ID Numbers: 256-KOB-0701
First Submitted: October 25, 2007
First Posted: October 26, 2007
Last Update Posted: October 26, 2007
Last Verified: October 2007

Additional relevant MeSH terms:
Mucositis
Stomatitis
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases